benzydamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3881 642-72-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • benzydamine HCl
  • benzydamine hydrochloride
  • benzydamide
  • benzydamine
  • benzidamine
  • benzindamine
A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.
  • Molecular weight: 309.41
  • Formula: C19H23N3O
  • CLOGP: 4.29
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 30.29
  • ALOGS: -3.80
  • ROTB: 7

Drug dosage:

DoseUnitRoute
0.15 g O
0.15 g R
9 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.53 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.28 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.80 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 156.45 38.16 63 5168 24313 63459478
Mouth ulceration 144.44 38.16 65 5166 32919 63450872
Skin candida 137.45 38.16 31 5200 1624 63482167
Neutropenic sepsis 135.64 38.16 51 5180 16387 63467404
Mucosal inflammation 111.45 38.16 61 5170 46867 63436924
Vaginal flatulence 106.83 38.16 29 5202 3264 63480527
Hypomagnesaemia 102.04 38.16 49 5182 28688 63455103
Chronic sinusitis 99.27 38.16 38 5193 12805 63470986
Proctitis 92.45 38.16 29 5202 5412 63478379
Constipation 89.44 38.16 101 5130 224842 63258949
Paraesthesia oral 87.60 38.16 39 5192 19217 63464574
Rectal haemorrhage 85.12 38.16 52 5179 48978 63434813
Diarrhoea 84.77 38.16 183 5048 715183 62768608
Female genital tract fistula 83.08 38.16 29 5202 7530 63476261
Procedural pain 80.28 38.16 38 5193 21531 63462260
Radiculopathy 79.39 38.16 29 5202 8582 63475209
Vaginal discharge 77.53 38.16 29 5202 9169 63474622
Nausea 72.48 38.16 192 5039 854279 62629512
Frequent bowel movements 69.03 38.16 35 5196 22987 63460804
Anaemia 68.15 38.16 101 5130 293329 63190462
Ejection fraction decreased 67.10 38.16 34 5197 22298 63461493
Excessive eye blinking 64.48 38.16 16 5215 1264 63482527
Oral candidiasis 63.55 38.16 33 5198 22765 63461026
Nervous system disorder 57.63 38.16 29 5202 18737 63465054
Rhinovirus infection 52.17 38.16 18 5213 4511 63479280
Intestinal dilatation 50.45 38.16 14 5217 1708 63482083
Weight decreased 50.01 38.16 85 5146 276713 63207078
Colitis ulcerative 48.68 38.16 29 5202 26062 63457729
Dyspepsia 45.88 38.16 49 5182 102147 63381644
Hypokalaemia 45.24 38.16 49 5182 103755 63380036
Lymphoedema 41.66 38.16 20 5211 11672 63472119
Vomiting 39.49 38.16 118 5113 559499 62924292

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutropenic sepsis 68.16 40.02 22 932 13745 34942232

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutropenic sepsis 178.43 35.62 70 6073 26994 79711251
Mouth ulceration 164.40 35.62 73 6070 38321 79699924
Skin candida 127.10 35.62 30 6113 2057 79736188
Vaginal flatulence 110.86 35.62 28 6115 2547 79735698
Mucosal inflammation 102.81 35.62 67 6076 75513 79662732
Macular degeneration 102.73 35.62 37 6106 11259 79726986
Chronic sinusitis 97.59 35.62 37 6106 12989 79725256
Constipation 88.84 35.62 109 6034 282941 79455304
Female genital tract fistula 87.55 35.62 28 6115 5947 79732298
Proctitis 85.52 35.62 28 6115 6404 79731841
Paraesthesia oral 84.61 35.62 38 6105 20433 79717812
Diarrhoea 83.35 35.62 198 5945 880291 78857954
Hypomagnesaemia 82.53 35.62 49 6094 46862 79691383
Vaginal discharge 81.44 35.62 28 6115 7435 79730810
Procedural pain 77.19 35.62 37 6106 23047 79715198
Radiculopathy 76.85 35.62 28 6115 8796 79729449
Nausea 70.59 35.62 196 5947 957000 78781245
Rectal haemorrhage 67.42 35.62 52 6091 76248 79661997
Frequent bowel movements 60.30 35.62 34 6109 29505 79708740
Oral candidiasis 60.20 35.62 34 6109 29594 79708651
Dyspepsia 58.98 35.62 56 6087 108631 79629614
Excessive eye blinking 56.25 35.62 15 6128 1686 79736559
Ejection fraction decreased 55.33 35.62 34 6109 34543 79703702
Nervous system disorder 47.07 35.62 28 6115 26828 79711417
Anaemia 46.10 35.62 104 6039 444911 79293334
Hypokalaemia 45.91 35.62 56 6087 143984 79594261
Intestinal dilatation 45.15 35.62 14 6129 2686 79735559
Lymphoedema 44.86 35.62 21 6122 12392 79725853
Neuropathy peripheral 43.52 35.62 54 6089 141251 79596994
Bleeding time prolonged 40.96 35.62 11 6132 1270 79736975
Colitis ulcerative 40.47 35.62 28 6115 34714 79703531
Rhinovirus infection 40.13 35.62 17 6126 7936 79730309
Lower respiratory tract infection 39.18 35.62 49 6094 129171 79609074
Vascular device infection 39.05 35.62 18 6125 10258 79727987
Weight decreased 38.98 35.62 85 6058 355113 79383132
Vomiting 38.09 35.62 125 6018 665703 79072542
Pyrexia 35.79 35.62 124 6019 678585 79059660

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AD02 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Other agents for local oral treatment
ATC G02CC03 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Antiinflammatory products for vaginal administration
ATC M01AX07 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Other antiinflammatory and antirheumatic agents, non-steroids
ATC M02AA05 MUSCULO-SKELETAL SYSTEM
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Antiinflammatory preparations, non-steroids for topical use
ATC R02AX03 RESPIRATORY SYSTEM
THROAT PREPARATIONS
THROAT PREPARATIONS
Other throat preparations
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:35337 analeptic
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:35499 hallucinogens
CHEBI has role CHEBI:36333 local anesthetics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.78 Basic
pKa2 1.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Soluble guanylate cyclase Enzyme EC50 5.99 CHEMBL

External reference:

IDSource
D01410 KEGG_DRUG
132-69-4 SECONDARY_CAS_RN
C0005099 UMLSCUI
CHEBI:94563 CHEBI
CHEMBL12610 ChEMBL_ID
CHEMBL1528134 ChEMBL_ID
D001591 MESH_DESCRIPTOR_UI
DB09084 DRUGBANK_ID
1927 INN_ID
4O21U048EF UNII
12555 PUBCHEM_CID
1425 RXNORM
003474 NDDF
004658 NDDF
331143003 SNOMEDCT_US
350307000 SNOMEDCT_US
421319000 SNOMEDCT_US

Pharmaceutical products:

None